Lombard gets all-clear to test AAA Aorfix graft in US clinical trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given Lombard Medical Technologies the go-ahead to begin a clinical trial of its Aorfix endovascular stent graft for treating abdominal aortic aneurysms (AAAs). The first part of the trial, which the UK firm said would begin this quarter, will be conducted at 20 centres and will involve over 250 patients with AAAs and with aortic neck angulations of 60degrees or less being treated with Aorfix. These patients will be compared with a control group of 110 subjects unsuitable for endovascular graft therapy, who will receive conventional open surgery. Recruitment is expected to take 12-15 months and patients will be followed up for a year. Aorfix is currently being commercialised in Europe, said the Didcot, Oxfordshire-based company.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.